产品展示更多>>
- Latanoprost 130209-82-4

- Latanoprost 130209-82-4
Latanoprost 130209-82-4
产品描述 描述 Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect.
纯度 >98%储存/保存方法 Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.基本信息 别名 拉坦前列腺素;外观 无色或微黄色油体可溶性/溶解性 10 mM in DMSO生物活性 靶点 Prostaglandin ReceptorIn vitro(体外研究) Benzalkonium chloride latanoprost (BAK-latanoprost) and 0.02% BAK induce significant apoptosis in the apical layers that correlated with the significant decrease of cell viability. Preservative-free latanoprost (PF-latanoprost) slightly decreases cell viability and few apoptotic cells are found in the superficial layers, without reaching statistical significance compared with PBS. Latanoprost (0.1 μM) significantly increases cell viability as compared with control. Meanwhile, 0.1 μM latanoprost results in the obvious promotion of neurite outgrowth similar to ciliary neurotrophic factor (CNTF) and simultaneously increases the levels of p-Akt and p-mTOR expression. Latanoprost can promote neurite outgrowth through an FP receptor-mediated modulation of the PI3K-Akt-mTOR signaling pathway. Latanoprost (0.03 or 0.3 μg/mL) and bimatoprost increase MMP-9 activity by 75% ± 27% and 75% ± 24%, respectively, in human CBSM cells.In vivo(体内研究) A single drop of latanoprost results in marked miosis, anterior bowing of the peripheral iris, narrowing of the iridocorneal angle, and shallowing of the anterior chamber of the beagle dog. Following latanoprost, the pupil diameter, ACA, and AOD (means) decreases 84%, 14%, and 16%, respectively.参考文献 参考文献 1. Patel SS and CM Spencer Latanoprost. Drugs Aging, 1996. 9(5): p. 363-78.
研究领域 研究领域 Drug DiscoverySmall Molecule DrugLead Compound DiscoveryLatanoprost 130209-82-4温馨提示:本产品仅作科研实验使用,不支持临床等研究
